(Q36170887)

12 August 2017

An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada (English)

1 reference

12 August 2017

0 references

0 references

invasive aspergillosis

1 reference

1 reference

1 reference

Coleman Rotstein

1

1 reference

12 August 2017

Michel Laverdière

series ordinal

2

1 reference

12 August 2017

Anne Marciniak

series ordinal

3

1 reference

12 August 2017

Farzad Ali

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Canadian Journal of Infectious Diseases & Medical Microbiology

12 August 2017

1 reference

12 August 2017

15

1 reference

12 August 2017

5

1 reference

12 August 2017

277-284

1 reference

Creative Commons Attribution 4.0 International

12 August 2017

start time

1 January 2004

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Invasive fungal infections in Canada from 1992 to 1994.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Antifungal therapy--state of the art at the beginning of the 21st century.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

The direct cost and incidence of systemic fungal infections

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Mortality and costs of acute renal failure associated with amphotericin B therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

The cost of treating systemic fungal infections

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Therapeutic outcome in invasive aspergillosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Number needed to treat (NNT): estimation of a measure of clinical benefit

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2094981

Number needed to treat (NNT)

23 September 2018

1 reference

12 December 2020

Estimating the true cost of amphotericin B

1 reference

12 December 2020

Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses

1 reference

12 December 2020

Invasive aspergillosis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2004/183087

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

18159506

1 reference